Cardiovascular imaging techniques

I read with interest Esteban Escolar and colleagues’ article on new tomographic cardiovascular imaging techniques. In my opinion, the greatest diagnostic advantage of multiple-slice spiral computed tomography (CT) angiography is in investigations of patients at high risk of coronary artery disease, contrary to the view of the authors. They do not point out the excessive radiation dosage to which the patient is exposed by multiple-slice spiral CT angiography: a scan requires a minimum of 850 mA of current and the radiation dose varies from 18 mSv to 22 mSv. Are we sure that conventional noninvasive cardiac tests (such as dobutamine stress echocardiography) are not adequate to identify myocardial ischemia in patients at low risk of coronary artery disease? What are the advantages of using coronary CT angiography for such patients, usually aged 45 years or younger, and exposing them to excessive radiation?

Massimo De Filippo
Maurizio Zompatori
Department of Clinical Science
Section of Radiological Science
University of Parma
Parma, Italy

REFERENCES

DOI:10.1503/cmaj.1060155

Industrial health research in Canada

In his commentary on the pharmaceutical industry, Henry Mintzberg recommends several measures that are already in place in Canada. He recommends firmer regulation of pricing, but Canada is unique in that it has 2 levels of price control, at the federal and provincial levels. He also recommends independent clearing houses for information on health products, but Canada already has a plethora of these at the federal and provincial levels, in addition to scientific bodies and journals. In addition, he suggests that direct-to-consumer advertising should be stopped, but it is currently forbidden in Canada.

A more important issue, in my opinion, is the unimpressive condition of industrial health research in Canada. Although we have the third-largest number of biotechnology companies in the world after the United States and the United Kingdom, our country is at the bottom of the Organisation for Economic Co-operation and Development’s ranking for industrial health research and development.

Unfortunately, Canadian discoveries are often developed elsewhere. Instead of blaming the pharmaceutical industry for developing and commercializing health products discovered by biotechnology companies, we should establish conditions that will convince them to do this work in Canada. Instead of finding fault with intellectual property regulations as they apply to novel health products, we should see that they are strengthened in Canada. Instead of taking issue with the pharmaceutical industry’s research priorities (saying, for example, that industry should study the causes of breast cancer and not its cures), we should make sure that the environment in Canada encourages industrial research and development. Instead of lamenting the increasing numbers of health researchers in industry, we should boost the appropriately small number of people doing industrial health research in Canada.

Mintzberg is world-renowned for his studies in management and strategic planning. He should now focus on developing a genuine pharmaceutical strategy for Canada: this must be a priority for our health care delivery system.

Yves Morin
Chair
Rx&D Health Research Foundation
Québec, Que.

REFERENCE
DOI:10.1503/cmaj.1060190

[The author responds:]

Yves Morin’s comments in response to my CMAJ article are true and not true. We control pharmaceutical prices, but do we do so adequately? We control the content of advertising, but certainly not the promotion of brand names. In any event, I was writing about the problem in general, because CMAJ is a respected journal outside Canada as well as within this country. With this in mind, my concern in the article was with abuses in the pharmaceutical industry, not with how we as Canadians can cash in on them.

Henry Mintzberg
Cleghorn Professor of Management Studies
McGill University
Montréal, Que.

REFERENCE
DOI:10.1503/cmaj.1060235